Inhaled treprostinil for Raynaud's attacks in scleroderma
Part of Heart & circulation, Skin clinical trials.
This study tests an inhaled medication called treprostinil to see if it can reduce the number and severity of Raynaud's attacks in people with scleroderma (systemic sclerosis). If you have frequent Raynaud's attacks, this treatment might help you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of systemic sclerosis (scleroderma).
- You must have a history of Raynaud's phenomenon and have had at least 12 attacks within the screening period.
- You cannot have more than 3 digital ulcers (sores on fingers) at screening, or a history of gangrene or amputation in the last 6 months.
- You cannot have certain lung conditions, severe high or low blood pressure, or bleeding disorders.
- You must not have used certain other blood vessel medications within the specified time before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called treprostinil to see if it can help people who have frequent Raynaud's attacks. It is for patients with primary or secondary Raynaud's (related to conditions like scleroderma or lupus) who still have attacks despite current treatments.
This program provides access to an inhaled medication called treprostinil for people who have pulmonary hypertension (high blood pressure in the lungs) related to interstitial lung disease (a type of lung scarring). The treatment aims to improve symptoms and quality of life.
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
This study tests whether switching from the oral medicine selexipag to an inhaled medicine called treprostinil can improve symptoms or side effects in people with pulmonary arterial hypertension (PAH). It may be an option if you are not getting enough benefit or are having trouble tolerating selexipag.
This trial tests an inhaled medication called treprostinil (Tyvaso) to see if it can help people with COPD who have low blood oxygen levels. You may qualify if you have chronic bronchitis, use oxygen at rest or during exercise, and meet specific lung function criteria.
This trial tests whether an inhaled medication called treprostinil (which helps open blood vessels in the lungs) can improve exercise ability in people who get high blood pressure in the lungs only during exercise. Participation involves taking the medication and doing exercise tests to see how well you do.
Hear when a new Raynaud's Phenomenon Secondary to Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.